Home/Pipeline/Crovalimab

Crovalimab

Paroxysmal Nocturnal Hemoglobinuria

Phase III / MarketedActive/ApprovedNCT04432584

Key Facts

Indication
Paroxysmal Nocturnal Hemoglobinuria
Phase
Phase III / Marketed
Status
Active/Approved
Company

About Chugai Pharmaceutical

Chugai Pharmaceutical's mission is to create innovative, best-in-class therapeutics that contribute to human health worldwide, with a strategic focus on oncology and niche specialty areas. Its defining achievement is the construction of a highly successful, decades-long strategic alliance with Roche, which provides a unique two-way pipeline flow, global scale, and financial stability. The company's strategy centers on maintaining a powerful independent R&D engine to generate proprietary assets while simultaneously co-developing and commercializing Roche's global portfolio in its key markets. This model has established Chugai as Japan's premier biopharmaceutical innovator and a vital node in Roche's global network.

View full company profile

Other Paroxysmal Nocturnal Hemoglobinuria Drugs

DrugCompanyPhase
CPR‑PNH‑001Chugai Pharmabody ResearchApproved